Clover Health Investments, Corp.
NASDAQ:CLOVMedical - Healthcare Plans
+$0.17 today
- Market cap
- $2.21B
- Beta
- 2.48
- P/E (TTM)
- -45.6
- EPS (TTM)
- -$0.11
Volume 8.05M
Average 7.31M
CLOV Operating Margin
Operating income as a percentage of revenue, showing the profitability of core operations.
Clover Health Investments, Corp.NASDAQ: CLOV
Operating Margin · Q2 FY2026 · quarter ended Jun 2026
Operating margin widens to 3.8%
Operating margin was 3.8% in Q2 FY2026, up 6.0 pp from a year earlier. On a trailing-twelve-month basis it was -0.7%, up 1.9 pp year over year. Over 3 fiscal years it widened by 21.7 pp.
Context
- Operating margin widened in 2 of the last 3 fiscal years.
What to watch
Whether operating margin reaches the consensus estimate from 3 analysts of 1.3% for the fiscal year ending Dec 2026, up from -4.4% in FY2025.
Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.
- Latest quarterJun 2026
- 3.8%+0.1 pp QoQ
- Last fiscal yearDec 2025
- -4.4%-1.1 pp YoY
- LTMJun 2026
- -0.7%+1.9 pp YoY
| Horizon | Past | Forecast | Difference |
|---|---|---|---|
| Quarter | +6.0 pp | +4.5 pp | -1.5 pp |
| 1 year | -1.1 pp | +5.8 pp | +6.9 pp |
| 3 years | +21.7 pp | +7.3 pp | -14.4 pp |
| 5 years | +8.4 pp | — | |
| 10 years | — | — |
Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.
Operating Margin history
Percent of revenue · from the income statement
- Latest · FY2025
- -4.4%
- Year-over-year change
- -1.1pp
| Period | Period end | Operating Margin | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | -4.4% | -1.1pp |
| FY2024 | 2024-12-31 | -3.3% | +13.0pp |
| FY2023 | 2023-12-31 | -16.3% | +9.9pp |
| FY2022 | 2022-12-31 | -26.1% | +17.1pp |
| FY2021 | 2021-12-31 | -43.3% | — |
Operating Margin vs competitors
How CLOV compares with its peers on the latest reported figures
- CLOV's LTM Jun 2026 operating margin of -0.7% is the 6th highest of the 7 companies compared; the peer median is 1.6%.
- Its year-over-year change of +1.9 pp is the 3rd highest of 7, against a peer median of -0.0 pp.
- Over three fiscal years its change of +21.7 pp compares with a peer median of -0.6 pp.
| Company | Period | LTM level | YoY | 3-year change |
|---|---|---|---|---|
| LTM Jun 2026 | 4.1% | +5.3 pp | +11.4 pp | |
| LTM Sep 2026 | 3.3% | -0.1 pp | -1.4 pp | |
| LTM Jun 2026 | 2.0% | -0.3 pp | +0.1 pp | |
| LTM Sep 2026 | 1.3% | +0.0 pp | -2.7 pp | |
| LTM Mar 2026 | 0.8% | +3.0 pp | +9.3 pp | |
| LTM Jun 2026 | -0.7% | +1.9 pp | +21.7 pp | |
| LTM Jun 2026 | -2.8% | -3.9 pp | -4.8 pp | |
| Peer median (excluding CLOV) | 1.6% | -0.0 pp | -0.6 pp | |
Competitors are the stored peer set for CLOV. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 1.47B | 1.1B | 1.26B | 1.37B | 1.92B |
| Cost of Revenue | 1.55B | 993.07M | 1B | 1.01B | 1.57B |
| Gross Profit | (79.18M) | 103.48M | 255.95M | 364.8M | 355.88M |
| Gross Margin | -5.4% | 9.4% | 20.3% | 26.6% | 18.5% |
| Research & Development | 0 | 0 | 0 | 0 | 0 |
| Selling, General & Admin | 445.75M | 482.4M | 440.25M | 408.93M | 176.32M |
| Operating Expenses | 557.81M | 390.14M | 461.28M | 410.55M | 441.43M |
| Depreciation & Amortization | 1.25M | 1.19M | 2.51M | 1.33M | 1.69M |
| EBITDA | (569.6M) | (252.03M) | (207.63M) | (44.94M) | (83.86M) |
| EBITDA Margin | -38.7% | -23.0% | -16.5% | -3.3% | -4.4% |
| Operating Income | (636.99M) | (286.66M) | (205.33M) | (45.75M) | (85.53M) |
| Operating Margin | -43.3% | -26.1% | -16.3% | -3.3% | -4.4% |
| Interest Income | 0 | 0 | 0 | 0 | 0 |
| Interest Expense | 16.91M | 1.36M | 7K | 0 | 0 |
| Other Income / Expenses | 49.24M | 32.08M | (4.82M) | (517K) | (20K) |
| Income Before Tax | (587.76M) | (254.58M) | (210.15M) | (46.27M) | (85.55M) |
| Pre-Tax Margin | -39.9% | -23.2% | -16.7% | -3.4% | -4.4% |
| Income Tax Expense | 0 | 0 | 0 | 0 | 0 |
| Net Income | (587.76M) | (339.57M) | (213.36M) | (43.01M) | (85.55M) |
| Net Margin | -39.9% | -31.0% | -16.9% | -3.1% | -4.4% |
| EPS (Basic) | (1.25) | (0.71) | (0.45) | (0.09) | (0.17) |
| EPS (Diluted) | (1.25) | (0.71) | (0.45) | (0.09) | (0.17) |
| Weighted Avg Shares | 470.85M | 476.24M | 482.18M | 490.02M | 517.24M |
| Weighted Avg Shares (Diluted) | 470.85M | 476.24M | 482.18M | 490.02M | 517.24M |
Clover Health Investments, Corp.
NASDAQ:CLOV
Intrinsic Alpha fair value
Locked
Current Price
$4.17
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.